Phase II Study of Everolimus Beyond Progression

Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer

This phase II trial studies how well everolimus and hormone therapy work in treating patients with hormone receptor positive breast cancer that has continued to spread (progressed) or returned after a period of improvement (recurred) on everolimus and exemestane hormone therapy. Everolimus is a chemotherapy drug that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen and progesterone are hormones that can cause the growth of breast cancer cells. Hormone therapy may fight breast cancer by lowering the amount of estrogen and progesterone the body makes. Giving everolimus with a different type of hormone therapy may be an effective treatment for breast cancer in patients who progressed on everolimus with exemestane.

Study Overview

• Status: Terminated
• Conditions: Stage IV Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Recurrent Breast Cancer; Estrogen Receptor-positive Breast Cancer; Progesterone Receptor-positive Breast Cancer; HER2-negative Breast Cancer
• Intervention / Treatment: Drug: tamoxifen citrate; Drug: letrozole; Drug: everolimus; Drug: anastrozole; Drug: fulvestrant; Drug: megestrol acetate

Detailed Description

PRIMARY OBJECTIVE:

Progression free survival in patients with advanced or metastatic breast cancer receiving everolimus plus hormonal therapy beyond first progression.

SECONDARY OBJECTIVES:

1. Clinical benefit rate (sum of stable disease, partial response, complete response).
2. Response rate (partial response and complete response).
3. Overall survival.
4. Safety, side effects and tolerability profile of everolimus.

OUTLINE:

Patients receive everolimus orally (PO) daily and a hormone therapy regimen chosen at the discretion of the investigator (anastrozole PO daily; letrozole PO daily; tamoxifen citrate PO daily; fulvestrant intramuscularly [IM] or PO on days 1, 15, and 29, and then monthly; megestrol acetate PO 4 times daily [QID]; or other regimen). Treatment continues in the absence of disease progression or unacceptable toxicity.

• Study Type: Interventional
• Enrollment (Actual): 3
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Georgia
    • Atlanta, Georgia, United States, 30308
      • Emory University Hospital Midtown
    • Atlanta, Georgia, United States, 30342
      • Emory Saint Joseph's Hospital
    • Atlanta, Georgia, United States, 30322
      • Emory University/Winship Cancer Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 17 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Estrogen (ER) and/or progesterone (PR)-positive at primary diagnosis and at metastatic diagnosis where tissue is available (defined as > or = 1% of staining nuclei)
• Progressive or recurrent breast cancer defined as disease progression or recurrence while on a combination of exemestane with everolimus
• Human epidermal growth factor receptor 2 (HER2)/neu-negative breast cancer by standard criteria (immunohistochemistry [IHC] < 3+ or fluorescence in situ hybridization [FISH] negative if IHC 2+) at primary diagnosis
• Histologically confirmed, measurable or evaluable disease; patients should have at least one measurable lesion; if applicable, Response Evaluation Criteria in Solid Tumors (RECIST) criteria should be used
• Life expectancy > 6 months
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• Absolute neutrophil count (ANC) > 1,500/µL
• Platelets ≥ 100,000/µL
• Hemoglobin > 10 g/dL
• Creatinine ≤ 1.5 x upper limit of normal (ULN)
• Bilirubin ≤ 1.5 x ULN
• International normalized ratio ≤ 1.3 (or ≤ 3 on anticoagulants)
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x ULN unless related to primary disease
• Signed informed consent
• Adequate birth control
• Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN; NOTE: in case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication

Exclusion Criteria:

• Prior treatment with everolimus other than in combination with hormonal therapy for treatment of breast cancer or prior treatment with another mammalian target of rapamycin (mTOR) inhibitor (sirolimus, temsirolimus) for any indication
• HER2 positive disease as defined by 3+ IHC or positive FISH (both in primary and metastatic sites)
• Active infection: temperature > 100 Fahrenheit (F), fever of unknown origin, active symptoms or signs of infection as defined by the investigator
• Uncontrolled central nervous system metastases
• Life-threatening, visceral metastases
• Pregnant or lactating women
• Prior chemotherapy within the last 4 weeks
• Prior radiation therapy within the last 4 weeks; prior radiation therapy to indicator lesion (unless objective disease recurrence or progression within the radiation portal has been documented since completion of radiation)
• Concomitant malignancies or previous malignancies within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
• History of significant cardiac disease, cardiac risk factors or uncontrolled arrhythmias
• Hypersensitivity to trial medications (everolimus)
• Emotional limitations, which the investigator judges could limit the patient's ability to follow up and comply with study procedures
• Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent
• Uncontrolled diabetes as defined by fasting serum glucose > 1.5 x ULN
• Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
• A known history of human immunodeficiency virus (HIV) seropositivity
• Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of EVEROLIMUS (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
• Patients with an active, bleeding diathesis
• Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of EVEROLIMUS)
• Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest

• Taking any of the following agents:

  • Chronic treatment with systemic steroids or another immunosuppressive agent (use of steroids as part of management of everolimus toxicities will be allowed)
  • Live vaccines
  • Patients who have received live attenuated vaccines within 1 week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, bacillus Calmette-Guérin (BCG), yellow fever, varicella and TY21a typhoid vaccines
  • Drugs or substances known to be inhibitors or inducers of the isoenzyme cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Treatment (everolimus, hormone therapy); Patients receive everolimus PO daily and a hormone therapy regimen chosen at the discretion of the investigator (anastrozole PO daily; letrozole PO daily; tamoxifen citrate PO daily; fulvestrant IM or PO on days 1, 15, and 29, and then monthly; megestrol acetate PO QID; or other regimen). Treatment continues in the absence of disease progression or unacceptable toxicity.

Drug: tamoxifen citrate; Given PO; Other Names: Nolvadex; TAM; tamoxifen; TMX; Drug: letrozole; Given PO; Other Names: CGS 20267; Femara; LTZ; Drug: everolimus; Given PO; Other Names: Afinitor; RAD001; 42-O-(2-hydroxy)ethyl rapamycin; Drug: anastrozole; Given PO; Other Names: Arimidex; ICI-D1033; ANAS; Drug: fulvestrant; Given IM or PO; Other Names: Faslodex; ICI 182,780; Drug: megestrol acetate; Given PO; Other Names: Megace; BDH 1298; Maygace; Megestil; Niagestin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Response Rate (Partial Response Plus Complete Response) Using RECIST	Study was terminated early due to difficulties with enrollment. No outcome measures were assessed.	Up to 2 years
Progression-free Survival (PFS)	Study was terminated early due to difficulties with enrollment. No outcome measures were assessed.	Up to 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical Benefit Rate (Response Rate Plus Stable Disease)	Study was terminated early due to difficulties with enrollment. No outcome measures were assessed.	Up to 2 years
Overall Survival (OS)	Study was terminated early due to difficulties with enrollment. No outcome measures were assessed.	From the initiation of alternate hormonal treatment in combination with everolimus to time of death from any cause, assessed up to 2 years
Incidence of Adverse Events Assessed Using Common Terminology Criteria for Adverse Events Version 4.0	Study was terminated early due to difficulties with enrollment. No outcome measures were assessed.	Up to 2 years

Collaborators and Investigators

• Sponsor: Emory University
• Collaborators: Novartis
• Investigators: Principal Investigator: Suchita Pakkala, MD, Emory University/Winship Cancer Institute

Study record dates

Study Major Dates

• Study Start (Actual): November 25, 2014
• Primary Completion (Actual): January 25, 2021
• Study Completion (Actual): January 25, 2021

Study Registration Dates

• First Submitted: October 17, 2014
• First Submitted That Met QC Criteria: October 17, 2014
• First Posted (Estimate): October 21, 2014

Study Record Updates

• Last Update Posted (Actual): April 5, 2022
• Last Update Submitted That Met QC Criteria: March 10, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Hormone Antagonists; Bone Density Conservation Agents; Aromatase Inhibitors; Steroid Synthesis Inhibitors; Estrogen Antagonists; Estrogen Receptor Antagonists; Contraceptive Agents, Hormonal; Contraceptive Agents; Reproductive Control Agents; Contraceptives, Oral; Contraceptive Agents, Female; Contraceptives, Oral, Synthetic; Contraceptives, Oral, Hormonal; Central Nervous System Stimulants; Selective Estrogen Receptor Modulators; Estrogen Receptor Modulators; Appetite Stimulants; Letrozole; Fulvestrant; Tamoxifen; Everolimus; Anastrozole; Megestrol; Megestrol Acetate
• Other Study ID Numbers: IRB00071229; NCI-2014-02092 (Registry Identifier: CTRP (Clinical Trial Reporting Program)); WINSHIP2563-13 (Other Identifier: Emory University/Winship Cancer Institute)